SARS-CoV-2 seroprevalence among blood donors in Uganda: 2019–2022

Simple item page
dc.contributor.authorBloch, Evan M
dc.contributor.authorKyeyune, Dorothy
dc.contributor.authorWhite, Jodie L
dc.contributor.authorDdungu, Henry
dc.contributor.authorAshokkumar, Swetha
dc.contributor.authorHabtehyimer, Feben
dc.contributor.authorBaker, Owen
dc.contributor.authorKasirye, Ronnie
dc.contributor.authorPatel, Eshan U.
dc.contributor.authorGrabowski, M. Kate
dc.contributor.authorMusisi, Ezra
dc.contributor.authorMoses, Khan
dc.contributor.authorHume, Heather A
dc.contributor.authorLubega, Irene
dc.contributor.authorShrestha, Ruchee
dc.contributor.authorMotevalli, Mahnaz
dc.contributor.authorFernandez, Reinaldo E
dc.contributor.authorReynolds, Steven J
dc.contributor.authorRedd, Andrew D
dc.contributor.authorWambongo Musana, Hellen
dc.contributor.authorDhabangi, Aggrey
dc.contributor.authorOuma, Joseph
dc.contributor.authorEroju, Priscilla
dc.contributor.authorLange, Telsa
dc.contributor.authorFowler, Mary Glenn
dc.contributor.authorMusoke, Philippa
dc.contributor.authorStramer, Susan L.
dc.contributor.authorWhitby, Denise
dc.contributor.authorZimmerman, Peter A
dc.contributor.authorMcCullough, Jeffrey
dc.contributor.authorSachithanandham, Jaiprasath
dc.contributor.authorPekosz, Andrew
dc.contributor.authorGoodrich, Raymond
dc.contributor.authorQuinn, Thomas C
dc.contributor.authorNess, Paul M.
dc.contributor.authorLaeyendecker, Oliver
dc.contributor.authorTobian, Aaron A. R.
dc.date.accessioned2023-09-12T09:35:36Z
dc.date.available2023-09-12T09:35:36Z
dc.date.issued2023-05-16
dc.description.abstractAbstract Abstract Background The true burden of COVID‐19 in low‐ and middle‐income countries remains poorly characterized, especially in Africa. Even prior to the availability of SARS‐CoV‐2 vaccines, countries in Africa had lower numbers of reported COVID‐19 related hospitalizations and deaths than other regions globally. Methods Ugandan blood donors were evaluated between October 2019 and April 2022 for IgG antibodies to SARS‐CoV‐2 nucleocapsid (N), spike (S), and five variants of the S protein using multiplexed electrochemiluminescence immunoassays (MesoScale Diagnostics, Rockville, MD). Seropositivity for N and S was assigned using manufacturer‐provided cutoffs and trends in seroprevalence were estimated by quarter. Statistically significant associations between N and S antibody seropositivity and donor characteristics in November–December 2021 were assessed by chi‐square tests. Results A total of 5393 blood unit samples from donors were evaluated. N and S seropositivity increased throughout the pandemic to 82.6% in January–April 2022. Among seropositive individuals, N and S antibody levels increased ≥9‐fold over the study period. In November–December 2021, seropositivity to N and S antibody was higher among repeat donors (61.3%) compared with new donors (55.1%; p = .043) and among donors from Kampala (capital city of Uganda) compared with rural regions ( p = .007). Seropositivity to S antibody was significantly lower among HIV‐seropositive individuals (58.8% vs. 84.9%; p = .009). Conclusions Despite previously reported low numbers of COVID‐19 cases and related deaths in Uganda, high SARS‐CoV‐2 seroprevalence and increasing antibody levels among blood donors indicated that the country experienced high levels of infection over the course of the pandemic.en_US
dc.description.sponsorshipDivision of Intramural Research, National Institute of Allergy and Infectious Diseases, Grant/Award Number: R01AI128779; Frederick National Laboratory for Cancer Research, Grant/Award Numbers: 75N91019D00024, HHSN261200800001E; National Heart and Lung Institute, Grant/Award Number: 1K23HL151826; National Institute of Diabetes and Digestive and Kidney Diseases, Grant/Award Number: R01DK131926; National Institute on Drug Abuse, Grant/Award Number:en_US
dc.identifier.citationBloch, Evan M., Dorothy Kyeyune, Jodie L. White, et al. 'SARS‐CoV‐2 Seroprevalence among Blood Donors in Uganda: 2019–2022', Transfusion (Philadelphia, Pa.), vol. 63/no. 7, (2023), pp. 1354-1365.en_US
dc.identifier.issnISSN 0041-1132
dc.identifier.issnEISSN 1537-2995
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/9193
dc.language.isoenen_US
dc.publisherJohn Wiley & Sons, Ltden_US
dc.subjectBlood donors, COVID-19, epidemiology, SARS-CoV-2, serological testing, Ugandaen_US
dc.titleSARS-CoV-2 seroprevalence among blood donors in Uganda: 2019–2022en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Transfusion - 2023 - Bloch (1).pdf
Size:
2.2 MB
Format:
Adobe Portable Document Format
Description:
Journal Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences